A Pan‐Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer
Cancer Reports · 2026
DOI: 10.1002/cnr2.70427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Yunjian Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Fatty Acids, Biomarkers, Tumor. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Key Medical Research Projects of Jiangsu Provincial Health Commission.
Abstract (Originalsprache)
Background
Breast cancer exhibits profound molecular heterogeneity. Each subtype is characterized by distinct biological features, therapeutic responses, and prognostic outcomes. However, a unifying feature across most breast cancer subtypes is an adipocyte‐enriched microenvironment. Dysregulated lipid metabolism drives tumor progression across subtypes.
Aims
We developed a universal prognostic model independent of molecular classification based on fatty acid metabolism‐related genes.
Methods
Prognostic fatty acid metabolism‐related genes were identified in the training set using univariate Cox regression. LASSO regression refined these genes to construct the fatty acid metabolic signature for prognosis (FAMOUS), enabling risk stratification. FAMOUS's prognostic utility was validated in the testing set and external cohort, and across molecular subtypes and therapies.
Results
FAMOUS comprises 15 genes. High FAMOUS scores independently predicted poor overall survival in the training set (HR = 4.97, 95% CI: 3.17–7.79; p < 0.001), testing set (HR = 7.39, 95% CI: 2.19–24.97; p = 0.001), and GSE72245 (HR = 7.97, 95% CI: 3.39–18.75; p < 0.001), after adjusting for molecular subtype, stage, and age. It stratified risk across Luminal A, Luminal B, HER2+, and TNBC subtypes and retained prognostic value in patients receiving chemotherapy, radiotherapy, endocrine therapy, or trastuzumab. High FAMOUS scores correlated with immune‐suppressive microenvironments, marked by downregulated immune‐related pathways and altered immune cell infiltration (e.g., reduced CD8+ T cells, enriched M2 macrophages), suggesting implications for immunotherapy patient stratification.
Conclusion
FAMOUS is a novel, pan‐subtype prognostic tool for breast cancer, transcending molecular classification and therapeutic modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical School of Nantong University, Nantong, China.
- School of Public Health, Nantong University, Nantong, China.
- Comprehensive Cancer Center, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Department of Thyroid and Breast Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Department of Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, China.
ORCID-Profile: Yunjian Song, Jiayue Li, Meiyue Zhu, Yi Xia, Deqiang Wang, Zhenhua Sun, Liang Ou, Lei Yang
Förderung
- Natural Science Foundation of Jiangsu Province
- Key Medical Research Projects of Jiangsu Provincial Health Commission
Zitieren
APA
Song, Y., Li, J., Zhu, M., Xia, Y., Wang, D., Sun, Z., Ou, L., & Yang, L. (2026). A Pan‐Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70427
Vancouver
Song Y, Li J, Zhu M, Xia Y, Wang D, Sun Z, et al. A Pan‐Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer. Cancer Reports. 2026. doi:10.1002/cnr2.70427
BibTeX
@article{Song2026,
author = {Song, Yunjian and Li, Jiayue and Zhu, Meiyue and Xia, Yi and Wang, Deqiang and Sun, Zhenhua and Ou, Liang and Yang, Lei},
title = {A Pan‐Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70427}
}
EUVIMED